NEW YORK (GenomeWeb News) – AstraZeneca and the Broad Institute today said they will collaborate on identifying new compounds that target bacterial and viral infections.

The alliance will employ Broad's expertise in bacterial genomics and biochemistry with its chemical library of 100,000 customized molecules known as Diversity-Oriented Synthesis compounds. The library is "designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets," the partners said in a joint statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.